These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 14626567

  • 1. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 3. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 4. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 7. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
    Zeman M, Zák A, Vecka M, Tvrzická E, Písaríková A, Stanková B.
    Cas Lek Cesk; 2005 Sep 15; 144(11):737-41. PubMed ID: 16335699
    [Abstract] [Full Text] [Related]

  • 8. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 15; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 9. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb 15; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 15; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 11. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 12. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669
    [Abstract] [Full Text] [Related]

  • 13. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
    Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, Ezetimibe/Simvastatin + Fenofibrate Study Group.
    Am Heart J; 2007 Feb 01; 153(2):335.e1-8. PubMed ID: 17239698
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.
    Pol Merkur Lekarski; 2003 Jul 01; 15(85):42-6. PubMed ID: 14593958
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
    Ren JY, Chen H, Luo Y.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb 01; 33(2):122-6. PubMed ID: 15924805
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 19. [Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin].
    Spagnolli W, Ramponi C, Focher C, Dal Piaz A, Torboli P, Miori R, De Venuto G.
    Recenti Prog Med; 1996 Nov 15; 87(11):538-42. PubMed ID: 9122535
    [Abstract] [Full Text] [Related]

  • 20. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.